Zhi Tong Cai Jing·2026-01-27 08:53Market Overview - The Hong Kong stock market showed a positive trend with the Hang Seng Index rising over 1%, closing at 27,126.95 points, an increase of 1.35% or 361.43 points, with a total turnover of 254.37 billion HKD [1] - The Hang Seng China Enterprises Index increased by 1.07% to 9,244.88 points, while the Hang Seng Tech Index rose by 0.5% to 5,754.72 points [1] Blue-Chip Stocks Performance - China Life (02628) led the blue-chip stocks, rising by 5.97% to 34.1 HKD, contributing 22.99 points to the Hang Seng Index [2] - A report from Citigroup anticipates a historic opportunity for life insurance stocks due to wealth reallocation, as retail investors seek higher reinvestment yields [2] - Other notable blue-chip performances include AIA (01299) up 4.09%, CSPC Pharmaceutical (01093) up 3.54%, while Hang Lung Properties (00101) and Hansoh Pharmaceutical (03692) faced declines of 4.51% and 4.37% respectively [2] Sector Highlights Technology Sector - Major tech stocks mostly rose, with Alibaba increasing nearly 3% and Tencent rising over 1% [3] - AI-related stocks saw significant gains, with MINIMAX surging by 26.48% and Kingsoft Cloud up by 9.74% [3][4] Insurance Sector - The insurance sector performed well, with China Life and AIA showing strong gains [5] - Reports indicate that 80% of new insurance policies this year are dividend insurance, reflecting strong demand for wealth management products [5] Precious Metals Sector - The precious metals sector experienced a downturn, with several stocks like Zhenfeng Gold and China Silver Group declining significantly [6][7] Notable Corporate Developments - Zijin Mining announced a major acquisition of Canadian company United Gold for 5.5 billion CAD (approximately 28 billion RMB), which will expand its asset base significantly [8] - Harbin Electric (01133) projected a net profit of approximately 2.65 billion RMB for the fiscal year 2025, a substantial increase from 1.686 billion RMB in the previous year [11] - Ying Si Intelligent (03696) entered a strategic cooperation agreement with Qilu Pharmaceutical for drug development, valued at over 931 million HKD [10]